Research output per year
Research output per year
Personal profile
Biographical details
Principal Consultant at Metis Cognition Ltd. with nearly two decades' experience of assisting pharmaceutical and biotechnology companies with the selection and successful integration of cognitive testing into their drug development programs. Recent successful projects have included the development of Brintellix with Lundbeck, Souvenaid with Nutricia and Encenicline with EnVivo Pharma. In the past 2 years I have worked with more than 40 organisations engaged in drug development, including 8 of the current 'Fortune' top 10 pharmaceutical companies. I am also an Associate Professor at the Alzheimer Center at the VU Medical Center in Amsterdam. Current activities include
i) the measurement and treatment of cognition in depression,
ii) the potential for blending drug and non-drug interventions in a variety of CNS disorders and iii) the further development of appropriate cognition tools for use in studies of prodromal and early Alzheimer's disease.
Specialties: Cognitive test selection and administration
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
External positions
Principal Consultant at Metis Cognition Ltd, Kilmington, UK, Metis Cognition Ltd, Kilmington, UK
Associate Professor , VUmc
Fingerprint
Dive into the research topics where John Harrison is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation
Rucker, J. J., Marwood, L., Ajantaival, R.-L. J., Bird, C., Eriksson, H., Harrison, J., Lennard-Jones, M., Mistry, S., Saldarini, F., Stansfield, S., Tai, S. J., Williams, S., Weston, N., Malievskaia, E. & Young, A. H., Jan 2022, In: Journal of Psychopharmacology. 36, 1, p. 114-125 12 p.Research output: Contribution to journal › Article › peer-review
Open Access48 Citations (Scopus) -
AADvac1, an active immunotherapy against pathological tau protein demonstrates disease-modifying effects in Alzheimer's disease: a placebo-controlled randomised phase 2 study.
Harrison, J., 1 Mar 2021, (Accepted/In press) In: Nature Medicine.Research output: Contribution to journal › Article › peer-review
-
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease
REVERSE-SD Study Investigators, 27 May 2021, In: Alzheimer's research & therapy. 13, 1, p. 106 106.Research output: Contribution to journal › Article › peer-review
Open Access56 Citations (Scopus) -
Rationale and study-design of a randomized, placebo-controlled, double-blind phase 2b trial to Evaluate Efficacy, Safety and Tolerability of an oral glutaminyl cyclase inhibitor Varoglutamstat (PQ912) in Study participants With MCI and Mild AD - VIVIAD
Harrison, J., 3 Mar 2021, (Accepted/In press) In: Alzheimer's research & therapy.Research output: Contribution to journal › Article › peer-review
Open Access -
Evaluation of the effect of Cooled HaEmodialysis on Cognitive function in patients suffering with end-stage KidnEy Disease (E-CHECKED): feasibility randomised control trial protocol
Harrison, J., 30 Sept 2020, In: Trials. 21, 1, 820.Research output: Contribution to journal › Article › peer-review
Open Access6 Citations (Scopus)